- Home
- OMER vs NETD Comparison
OMER vs NETD Comparison
Compare OMER & NETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- NETD
- Stock Information
- Founded
- OMER 1994
- NETD 2023
- Country
- OMER United States
- NETD United States
- Employees
- OMER N/A
- NETD N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- NETD
- Sector
- OMER Health Care
- NETD
- Exchange
- OMER Nasdaq
- NETD Nasdaq
- Market Cap
- OMER 397.1M
- NETD 417.9M
- IPO Year
- OMER 2009
- NETD 2023
- Fundamental
- Price
- OMER $3.22
- NETD $11.03
- Analyst Decision
- OMER Buy
- NETD
- Analyst Count
- OMER 4
- NETD 0
- Target Price
- OMER $22.50
- NETD N/A
- AVG Volume (30 Days)
- OMER 1.2M
- NETD 205.2K
- Earning Date
- OMER 05-15-2025
- NETD 01-01-0001
- Dividend Yield
- OMER N/A
- NETD N/A
- EPS Growth
- OMER N/A
- NETD N/A
- EPS
- OMER N/A
- NETD 0.34
- Revenue
- OMER N/A
- NETD N/A
- Revenue This Year
- OMER N/A
- NETD N/A
- Revenue Next Year
- OMER $2,447.88
- NETD N/A
- P/E Ratio
- OMER N/A
- NETD $32.33
- Revenue Growth
- OMER N/A
- NETD N/A
- 52 Week Low
- OMER $3.00
- NETD $10.50
- 52 Week High
- OMER $13.60
- NETD $11.10
- Technical
- Relative Strength Index (RSI)
- OMER 23.29
- NETD 61.56
- Support Level
- OMER $3.79
- NETD $10.97
- Resistance Level
- OMER $6.58
- NETD $11.03
- Average True Range (ATR)
- OMER 0.59
- NETD 0.02
- MACD
- OMER -0.33
- NETD -0.00
- Stochastic Oscillator
- OMER 5.43
- NETD 50.00
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.